Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the deadliest malignancies worldwide due to the lack of effective treatments. Chemoprevention in high-risk patients is a promising, alternative strategy. In this study, pioglitazone was investigated for its ability to prevent hepatocarcinogenesis...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Gastrointest Surg
Autors principals: Li, Shen, Ghoshal, Sarani, Sojoodi, Mozhdeh, Arora, Gunisha, Masia, Ricard, Erstad, Derek J., Lanuti, Michael, Hoshida, Yujin, Baumert, Thomas F., Tanabe, Kenneth K., Fuchs, Bryan C.
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2018
Matèries:
2018 SSAT Plenary Presentation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6328630/
https://ncbi.nlm.nih.gov/pubmed/30367397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11605-018-4004-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars